NCT04202796 (CATCH-Registry) is a clinical trial of Catheter ablation in Congenital Heart Disease, sponsored by Paris Cardiovascular Research Center (Inserm U970).

Who is sponsoring NCT04202796?

NCT04202796 is sponsored by Paris Cardiovascular Research Center (Inserm U970).

What drugs are being tested in NCT04202796?

Interventions in NCT04202796: Catheter ablation.

What condition does NCT04202796 study?

NCT04202796 studies Congenital Heart Disease, Arrhythmia.

Is NCT04202796 still recruiting?

NCT04202796 is currently status unknown. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT04202796: CATCH-Registry

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Catheter Ablation in Congenital Heart Disease: French National Prospective Registry

Status unknown Last updated 9 March 2021

What this trial tests

trial testing Catheter ablation in Congenital Heart Disease in 300 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2021

31 December 2023

Quick facts

Lead sponsor	Paris Cardiovascular Research Center (Inserm U970)
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	31 December 2023
Sites	1 location across France

Drugs / interventions tested

Catheter ablation

Conditions studied

Congenital Heart Disease — all drugs for Congenital Heart Disease →
Arrhythmia — all drugs for Arrhythmia →

Sponsor

Paris Cardiovascular Research Center (Inserm U970)

Who can join

Eligibility, any sex, with Congenital Heart Disease or Arrhythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Arrhythmias represent one of the main late complications in patients with congenital heart disease. Atrial arrhythmias are associated with a significant morbidity and are the first cause of urgent hospitalization, and sudden death from ventricular arrhythmias is a leading cause of death in this population. The exponential increase of the number of patients with congenital heart disease and the improvement of ablative technologies are associated with a significant increase of the number of catheter ablation procedures. Most of available studies are retrospective or include a limited number of patients. The aim of this study is to assess the efficacy of catheter ablation in patients with congenital heart disease through a national prospective registry. Secondary objectives are i) to identify factors associated with catheter ablation efficacy in different cardiac defects, ii) to describe complications associated with catheter ablation in this specific population, and iii) to assess the impact of catheter ablation on quality of life of patients with congenital heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Catheter ablation

Trials testing the same drug.

NCT07445334 — Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes · NA · not yet recruiting
NCT06632925 — Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Soft · active not recruiting
NCT06556485 — Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure · NA · recruiting
NCT06560047 — Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure · NA · recruiting
NCT06182566 — Hybrid Persistent Atrial Fibrillation Ablation in Heart Failure · NA · withdrawn

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting

Other Paris Cardiovascular Research Center (Inserm U970) trials

Trials by the same sponsor.

NCT04205461 — Prospective Evaluation of Programmed Ventricular Stimulation Before Pulmonary Valve Replacement in Patients With Tetralo · unknown
NCT04842851 — Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle · completed
NCT05349162 — Epicardial vs. Transvenous ICDs in Children · completed
NCT07291544 — Management of Supraventricular Tachycardias in Children · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04202796 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paris Cardiovascular Research Center (Inserm U970)
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04202796.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing